Patents by Inventor Sergey Rodin

Sergey Rodin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240141296
    Abstract: The present invention relates to methods for culturing and isolating cells such as multipotent stem cells or multipotent progenitor cells. The methods of the invention comprise using the human CD105 polypeptide as a cell culture substrate. The cells obtained according to the methods of the invention are capable of forming colony forming unit-fibroblasts (CFU-Fs). Cell lines comprising such cells are useful for the treatment of medical conditions, such as acute respiratory distress syndrome (ARDS).
    Type: Application
    Filed: February 24, 2022
    Publication date: May 2, 2024
    Inventors: Karl-Henrik Grinnemo, Oscar Simonson, Sergey Rodin
  • Patent number: 10829733
    Abstract: Compositions and processes for culturing human stem cells in vitro in an undifferentiated state are disclosed. In this regard, human embryonic stem cells proliferated and maintained their pluripotency when cultured on plates coated with recombinant laminin-10 (laminin-511).
    Type: Grant
    Filed: March 17, 2010
    Date of Patent: November 10, 2020
    Assignee: BIOLAMINA AB
    Inventors: Karl Tryggvason, Sergey Rodin, Anna Domogatskaya
  • Patent number: 10240124
    Abstract: The present disclosure related to isolated laminin-521, methods for making recombinant laminin-521, host cells that express recombinant laminin-521, and compositions containing laminin-521. Laminin-521 can maintain stem cells in vitro pluripotency, enable self-renewal, and enable single cell survival of human embryonic stem cells. When pluripotent human embryonic stem cells are cultured on plates coated with recombinant laminin-521 (laminin-11), in the absence of differentiation inhibitors or feeder cells, the embryonic stem cells proliferate and maintain their pluripotency. It has also been discovered that human recombinant laminin-521 (laminin-11) provides single cell survival of stem cells after complete dissociation into a single cell suspension. Useful cell culture mediums containing at most 3.9 ng/ml of beta fibroblast growth factor (bFGF) are also described herein.
    Type: Grant
    Filed: September 19, 2012
    Date of Patent: March 26, 2019
    Assignee: BioLamina AB
    Inventors: Karl Tryggvason, Sergey Rodin
  • Patent number: 10138292
    Abstract: The present disclosure related to isolated laminin-521, methods for making recombinant laminin-521, host cells that express recombinant laminin-521, and compositions containing laminin-521. Laminin-521 can maintain stem cells in vitro pluripotency, enable self-renewal, and enable single cell survival of human embryonic stem cells. When pluripotent human embryonic stem cells are cultured on plates coated with recombinant laminin-521 (laminin-11), in the absence of differentiation inhibitors or feeder cells, the embryonic stem cells proliferate and maintain their pluripotency. It has also been discovered that human recombinant laminin-521 (laminin-11) provides single cell survival of stem cells after complete dissociation into a single cell suspension. Useful cell culture mediums containing at most 3.9 ng/ml of beta fibroblast growth factor (bFGF) are also described herein.
    Type: Grant
    Filed: December 16, 2011
    Date of Patent: November 27, 2018
    Assignee: BIOLAMINA AB
    Inventors: Karl Tryggvason, Sergey Rodin
  • Patent number: 9534038
    Abstract: The present disclosure provides isolated laminin-421, methods for making recombinant laminin-421, and host cells that express recombinant laminin-421. The present disclosure also provides nucleic acid sequences encoding full length human laminin ?2 chain, expression vectors and host cells thereof.
    Type: Grant
    Filed: March 1, 2012
    Date of Patent: January 3, 2017
    Assignee: BIOLAMINA AB
    Inventors: Karl Tryggvason, Sergey Rodin
  • Patent number: 8951799
    Abstract: The present disclosure is directed to the development of compositions, such as extracellular matrices, and processes for using the same, that both maintain stem cells in vitro pluripotency and enable self-renewal. In this regard, it has been discovered that when pluripotent mouse and human embryonic stem cells are cultured on plates coated with recombinant laminin-10 (laminin-511) or their functional domains, in the absence of differentiation inhibitors or feeder cells, the embryonic stem cells proliferated and maintained their pluripotency.
    Type: Grant
    Filed: August 25, 2009
    Date of Patent: February 10, 2015
    Assignee: BioLamina AB
    Inventors: Anna Domogatskaya, Sergey Rodin, Karl Tryggvason
  • Publication number: 20140315306
    Abstract: The present disclosure related to isolated laminin-521, methods for making recombinant laminin-521, host cells that express recombinant laminin-521, and compositions containing laminin-521. Laminin-521 can maintain stem cells in vitro pluripotency, enable self-renewal, and enable single cell survival of human embryonic stem cells. When pluripotent human embryonic stem cells are cultured on plates coated with recombinant laminin-521 (laminin-11), in the absence of differentiation inhibitors or feeder cells, the embryonic stem cells proliferate and maintain their pluripotency. It has also been discovered that human recombinant laminin-521 (laminin-11) provides single cell survival of stem cells after complete dissociation into a single cell suspension. Useful cell culture mediums containing at most 3.9 ng/ml of beta fibroblast growth factor (bFGF) are also described herein.
    Type: Application
    Filed: September 19, 2012
    Publication date: October 23, 2014
    Inventors: Karl Tryggvason, Sergey Rodin
  • Patent number: 8722405
    Abstract: The present disclosure is directed to the development of compositions, such as extracellular matrices, and processes for using the same, for culturing stem cells in vitro in an undifferentiated state. In this regard, it has been discovered that when pluripotent mouse and human embryonic stem cells are cultured on plates coated with recombinant laminin-10 (laminin-511) or laminin-5 (laminin-322), or their functional domains, the embryonic stem cells proliferated and maintained their pluripotency.
    Type: Grant
    Filed: January 4, 2008
    Date of Patent: May 13, 2014
    Inventors: Karl Tryggvason, Anna Domogatskaya, Sergey Rodin
  • Patent number: 8415156
    Abstract: The present disclosure related to isolated laminin-521, methods for making recombinant laminin-521, host cells that express recombinant laminin-521, and compositions containing laminin-521. Laminin-521 can maintain stem cells in vitro pluripotency, enable self-renewal, and enable single cell survival of human embryonic stem cells. When pluripotent human embryonic stem cells are cultured on plates coated with a matrix of recombinant laminin-521 (laminin 11), in the absence of differentiation inhibitors or feeder cells, the embryonic stem cells proliferate and maintain their pluripotency. It has also been discovered that human recombinant laminin-521 (laminin-11) provides single cell survival of stem cells after complete dissociation into a single cell suspension. Useful cell culture mediums containing at most 3.9 ng/ml of beta fibroblast growth factor (bFGF) are also described herein.
    Type: Grant
    Filed: December 16, 2011
    Date of Patent: April 9, 2013
    Assignee: Biolamina AB
    Inventors: Karl Tryggvason, Sergey Rodin
  • Publication number: 20120302512
    Abstract: The present disclosure provides isolated laminin-421, methods for making recombinant laminin-421, and host cells that express recombinant laminin-421. The present disclosure also provides nucleic acid sequences encoding full length human laminin ?2 chain, expression vectors and host cells thereof.
    Type: Application
    Filed: March 1, 2012
    Publication date: November 29, 2012
    Applicant: BioLamina AB
    Inventors: Karl Tryggvason, Sergey Rodin
  • Publication number: 20120156782
    Abstract: The present disclosure related to isolated laminin-521, methods for making recombinant laminin-521, host cells that express recombinant laminin-521, and compositions containing laminin-521. Laminin-521 can maintain stem cells in vitro pluripotency, enable self-renewal, and enable single cell survival of human embryonic stem cells. When pluripotent human embryonic stem cells are cultured on plates coated with recombinant laminin-521 (laminin-11), in the absence of differentiation inhibitors or feeder cells, the embryonic stem cells proliferate and maintain their pluripotency. It has also been discovered that human recombinant laminin-521 (laminin-11) provides single cell survival of stem cells after complete dissociation into a single cell suspension. Useful cell culture mediums containing at most 3.9 ng/ml of beta fibroblast growth factor (bFGF) are also described herein.
    Type: Application
    Filed: December 16, 2011
    Publication date: June 21, 2012
    Applicant: BioLamina AB
    Inventors: Karl Tryggvason, Sergey Rodin
  • Publication number: 20120156254
    Abstract: The present disclosure related to isolated laminin-521, methods for making recombinant laminin-521, host cells that express recombinant laminin-521, and compositions containing laminin-521. Laminin-521 can maintain stem cells in vitro pluripotency, enable self-renewal, and enable single cell survival of human embryonic stem cells. When pluripotent human embryonic stem cells are cultured on plates coated with a matrix of recombinant laminin-521 (laminin 11), in the absence of differentiation inhibitors or feeder cells, the embryonic stem cells proliferate and maintain their pluripotency. It has also been discovered that human recombinant laminin-521 (laminin-11) provides single cell survival of stem cells after complete dissociation into a single cell suspension. Useful cell culture mediums containing at most 3.9 ng/ml of beta fibroblast growth factor (bFGF) are also described herein.
    Type: Application
    Filed: December 16, 2011
    Publication date: June 21, 2012
    Applicant: BIOLAMINA AB
    Inventors: KARL TRYGGVASON, SERGEY RODIN
  • Publication number: 20100323443
    Abstract: The present disclosure is directed to the development of compositions, such as extracellular matrices, and processes for using the same, that both maintain stem cells in vitro pluripotency and enable self-renewal. In this regard, it has been discovered that when pluripotent mouse and human embryonic stem cells are cultured on plates coated with recombinant laminin-10 (laminin-511) or their functional domains, in the absence of differentiation inhibitors or feeder cells, the embryonic stem cells proliferated and maintained their pluripotency.
    Type: Application
    Filed: August 25, 2009
    Publication date: December 23, 2010
    Inventors: Anna Domogatskaya, Sergey Rodin, Karl Tryggvason
  • Publication number: 20100203635
    Abstract: Compositions and processes for culturing human stem cells in vitro in an undifferentiated state are disclosed. In this regard, human embryonic stem cells proliferated and maintained their pluripotency when cultured on plates coated with recombinant laminin-10 (laminin-511).
    Type: Application
    Filed: March 17, 2010
    Publication date: August 12, 2010
    Inventors: Karl Tryggvason, Sergey Rodin, Anna Domogatskaya
  • Publication number: 20080213885
    Abstract: The present disclosure is directed to the development of compositions, such as extracellular matrices, and processes for using the same, for culturing stem cells in vitro in an undifferentiated state. In this regard, it has been discovered that when pluripotent mouse and human embryonic stem cells are cultured on plates coated with recombinant laminin-10 (laminin-511) or laminin-5 (laminin-322), or their functional domains, the embryonic stem cells proliferated and maintained their pluripotency.
    Type: Application
    Filed: January 4, 2008
    Publication date: September 4, 2008
    Inventors: Karl Tryggvason, Anna Domogatskaya, Sergey Rodin